首页 › 弥漫性大B细胞淋巴瘤 › 俄亥俄州 › Cincinnati
Cincinnati OH 弥漫性大B细胞淋巴瘤临床试验
11项针对 弥漫性大B细胞淋巴瘤的研究正在 Cincinnati及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
招募中2/3 期
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood · 距离 8 英里
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood · 距离 8 英里
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
招募中2 期
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 距离 15 英里
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- University of Cincinnati Medical Center, Cincinnati
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中观察性研究
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
招募中1 期
- University of Cincinnati, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- University of Cincinnati, Cincinnati
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY21 项研究
- Baldwin Park, CA19 项研究
- Chicago, IL18 项研究
- Los Angeles, CA17 项研究
- Houston, TX17 项研究
- Milwaukee, WI16 项研究
- Boston, MA16 项研究
- Portland, OR15 项研究
- Philadelphia, PA15 项研究
- Nashville, TN14 项研究
- Durham, NC14 项研究
- Dallas, TX13 项研究
Cincinnati的其他研究
- 非小细胞肺癌35 项研究
- 癌症（所有类型）28 项研究
- 乳腺癌25 项研究
- 心力衰竭24 项研究
- 结直肠癌21 项研究
- 肥胖症20 项研究
- 转移性癌症20 项研究
- 急性髓系白血病20 项研究
- 肺癌19 项研究
- 卵巢癌19 项研究
- 前列腺癌18 项研究
- 黑色素瘤17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月29日。每项研究自行设定入选标准，由研究团队决定谁能参与。